Literature DB >> 21194794

Cost-analysis of an intensive care unit closure due to an imipenem-resistant oxa-23 Acinetobacter baumannii outbreak.

R Garlantézec, C Bourigault, J M Boles, G Prat, R Baron, J M Tonnelier, M Cosse, M Lefevre, S Jourdain, G Lelay, L Daniel, M Virmaux, I Le Du, D Tande, A Renault, B Lejeune.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21194794     DOI： 10.1016/j.jhin.2010.09.027

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN： 0195-6701            Impact factor:   3.926


× No keyword cloud information.
  6 in total

1.  Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii-calcoaceticus complex.

Authors:  Teena Chopra; Dror Marchaim; Paul C Johnson; Reda A Awali; Hardik Doshi; Indu Chalana; Naomi Davis; Jing J Zhao; Jason M Pogue; Sapna Parmar; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

2.  Clostridium difficile multidisciplinary team root cause analysis: impact on clinical care and circumvention of financial penalties posed by clinical commissioning groups, but at what cost?

Authors:  Kordo Saeed; Christina Petridou; Hazel Gray; Matthew Dryden; Karen Davis-Blues; Sheryl Lucero; Natalie Parker; Taryn Keyser; Tanya Matthews; Nick Cortes; Stephen Kidd; Claire Thomas; Heather Peacock; Joanna Hornzee; Bruce Wake
Journal:  J Infect Prev       Date:  2017-08-21

Review 3.  Strategic measures for the control of surging antimicrobial resistance in Hong Kong and mainland of China.

Authors:  Vincent C C Cheng; Sally C Y Wong; Pak-Leung Ho; Kwok-Yung Yuen
Journal:  Emerg Microbes Infect       Date:  2015-02-11       Impact factor: 7.163

4.  A multi-center study on the risk factors of infection caused by multi-drug resistant Acinetobacter baumannii.

Authors:  Huiping Huang; Borong Chen; Gang Liu; Jing Ran; Xianyu Lian; Xinhua Huang; Nan Wang; Zhengjie Huang
Journal:  BMC Infect Dis       Date:  2018-01-05       Impact factor: 3.090

5.  An intervention to control an ICU outbreak of carbapenem-resistant Acinetobacter baumannii: long-term impact for the ICU and hospital.

Authors:  Eli Ben-Chetrit; Yonit Wiener-Well; Emil Lesho; Puah Kopuit; Chaya Broyer; Liora Bier; Marc V Assous; Shmuel Benenson; Matan J Cohen; Patrick T McGann; Erik Snesrud; Phillip D Levin
Journal:  Crit Care       Date:  2018-11-21       Impact factor: 9.097

6.  Clinical Efficacy and Nephrotoxicity of the Loading Dose Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients.

Authors:  Wasan Katip; Suriyon Uitrakul; Peninnah Oberdorfer
Journal:  Pharmaceutics       Date:  2021-12-24       Impact factor: 6.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.